Status | Study |
Recruiting |
Study Name: Phase 1B Study in Subjects With Small to Medium Primary Choroidal Melanoma Condition: Uveal Melanoma Ocular Melanoma Date: 2017-02-06 Interventions: Drug: Light-activated AU-011 Study treatment |
Recruiting |
Study Name: The Role of Inflammation in Ocular Tumours Condition: Ocular Melanoma Date: 2016-09-16 Interventions: Other: cSLO imaging |
Recruiting |
Study Name: Percutaneous Hepatic Perfusion vs Best Alternative Care in Patients With Hepatic-dominant Ocular Melanoma Condition: Melanoma, Ocular Date: 2016-02-01 Interventions: Procedure: Melphalan Melphalan |
Recruiting |
Study Name: Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma Condition: Ocular Melanoma Date: 2013-07-02 Interventions: Drug: Sorafenib Sorafenib will |
Active, not recruiting |
Study Name: Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery Condition: Recurrent Uveal Melanoma Stage III Uveal Melanoma Stage II Date: 2013-04-16 Interventions: Drug: Cabozantinib S-malate Gi |
Active, not recruiting |
Study Name: Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma Condition: Metastatic Ocular Melanoma Metastatic Uveal Melanoma Date: 2013-03-15 Interventions: Drug: Aldesleukin Aldeskeukin |
Not yet recruiting |
Study Name: Definity for Ultrasound of Intraocular Tumors Condition: Ocular Melanoma Date: 2013-02-28 |
Suspended |
Study Name: Vorinostat in Treating Patients With Metastatic Melanoma of the Eye Condition: Ocular Melanoma With Extraocular Extension Recurrent Uveal Mela Date: 2012-04-26 Interventions: Other: Laboratory Biomarker Analysis |
Completed |
Study Name: THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced Disease Condition: Ocular Melanoma Date: 2010-12-29 Interventions: Drug: Ipilimumab Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks |
Active, not recruiting |
Study Name: STA-9090(Ganetespib) in Metastatic Ocular Melanoma Condition: Ocular Melanoma Date: 2010-09-10 Interventions: Drug: STA-9090 Given intravenously once week or twice a week for three weeks of a four week cycle |